Our Science

Focus

Lemma Pharmaceuticals a preclinical stage anti-tumor agent development company that specializes in reformulating and enhancing the therapeutic index of potent agents approved for human use that face pharmacokinetic challenges.

A Novel Nanoparticle Based Platform Integrating Potent Anti-Tumor Agents able to Overcome Resistant Solid Tumors Such as Glioblastoma, Metastatic Melanoma, Breast, Pancreatic and Lung Cancers.

Copyright © Lemma Pharmaceuticals, Inc. All Rights Reserved.

Our integrated nanoparticle – drug platform “LipoStaur” overcomes resistant tumor cells, is selective for tumors, and has low systemic toxicity.

Glioblastoma multiforme (GBM) is the most common and deadliest of the malignant primary brain tumors in adults and is notoriously resistant to current therapeutics.